Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Friday, December 15, 2017

Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis, announced today that its Special Meeting of Stockholders scheduled for and convened on December 1, 2017 (the "Special Meeting"), was adjourned to achieve a quorum on the proposals set forth in Jaguar's definitive proxy statement on Schedule 14A, which was filed with the Securities and Exchange Commission (SEC) on November 20, 2017.

The Special Meeting has been adjourned to 8:00 a.m. Pacific Standard Time/11:00 a.m. Eastern Standard Time on Friday, December 15, 2017, at the offices of the Company at 201 Mission Street, Suite 2375, San Francisco, CA, 94105.

During the period of the adjournment, Jaguar will continue to solicit proxies from its stockholders with respect to the proposals set forth in the proxy statement. Only stockholders of record on the record date of November 13, 2017 are entitled to and are being requested to vote. If a stockholder has previously submitted its proxy card and does not wish to change its vote, no further action is required by such stockholder.

The Company encourages all stockholders who have not yet voted to do so before December 14, 2017 at 11:59 p.m. (Pacific Standard Time).

How You Can Vote

The stockholders may vote by internet at www.investorvote.com/JAGX, or by telephone at 800-652-VOTE (8683) within the USA, US territories & Canada on a touch tone telephone, or by returning a properly executed proxy card.

No changes have been made to the proposals to be voted on by stockholders at the Special Meeting. The Company's proxy statement and any other materials filed by the Company with the SEC remain unchanged and can be obtained free of charge at the SEC's website at www.sec.gov.

The Board and management of Jaguar recommend that you vote FOR the approval of each of the proposals before the stockholders at the Special Meeting.

Important Information

This material may be deemed to be solicitation material in respect of the solicitation of proxies from stockholders in connection with the Special Meeting. Jaguar has filed with the SEC and mailed to its stockholders a proxy statement in connection with the Special Meeting, and advises its stockholders to read the proxy statement and any and all supplements and amendments thereto because they contain important information. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at www.sec.gov. The proxy statement and proxy card are also available on the Company’s corporate website https://jaguar.health.